ReviewNutrients2022
Alkaline Phosphatase: An Old Friend as Treatment Target for Cardiovascular and Mineral Bone Disorders in Chronic Kidney Disease.
Review in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 2 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- Adynamic bone disorder in chronic kidney disease: meta-analysis and narrative review of potential biomarkers as diagnosis and therapeutic targets.Renal failure · 2025Pooled it
- Pooled it
- Bovine alkaline phosphatase in health and disease: A bibliometric and narrative review.Veterinary and animal science · 2026Review
- Vascular calcification: pathogenic mechanisms, signaling crosstalk and translational therapeutics.Signal transduction and targeted therapy · 2026Review
- TNALP associated calcium phosphate microdeposition contributes to thoracic aortic dissection susceptibility.Communications biology · 2026Article
- Plant-Based Functional Custard Enriched with Vitamin DFoods (Basel, Switzerland) · 2026Article
- Biological signature of dietary patterns in older adults: findings from a population-based study.BMC medicine · 2026Article
- Preoperative Serum Alkaline Phosphatase Predicts Arteriovenous Fistula Maturation Failure.Kidney international reports · 2026Article
- Optimal dietary nano-VD₃ enhances growth performance and bone development in broilers through remodeling the gut microbiome and metabolites.BMC veterinary research · 2026Article
- Bone turnover markers in the management of CKD-associated osteoporosis-a European consensus.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Review
- Multi-omics analysis of genetic drivers linking aortic stenosis and left ventricular diastolic dysfunction in heart failure.BioData mining · 2026Article
- Development of bone alkaline phosphatase-specific monoclonal antibodies and immunoassay exhibiting low cross-reactivity to liver isoform.JBMR plus · 2026Article
- Sex-specific prediction models for aortic aneurysm integrating traditional clinical risk factors and proteomic profiles: a large-scale prospective study from the UK Biobank.Biology of sex differences · 2026Article
- Liver fraction of circulating alkaline phosphatase is elevated in chronic kidney disease and associates with mortality in patients treated with haemodialysis.Clinical kidney journal · 2026Article
- Employment of the Albumin to Alkaline Phosphatase Ratio to Predict All-cause Mortality and Cardiovascular and Cerebrovascular Mortality in Adults Aged At Least 60 Years: An Analysis From NHANES 2003-2018.Reviews in cardiovascular medicine · 2026Article
- Ecto-5'-nucleotidase/CD73 reduces COX-2 expression in activated macrophages.Scientific reports · 2026Article
- Osteoprotective Effects and In Silico Profiling of Parinari curatellifolia Planch. Ex Benth. (Chrysobalanaceae) Extract on Acute Plasmodium berghei-Compromised Rat Bone.Chemistry & biodiversity · 2026Article
- Effect of substituting fishmeal with black soldier fly and mealworm larvae meal on nutrient digestibility, body and mineral composition ofOpen veterinary journal · 2026Article
- Article
- Prognostic Factors Analysis in Patients with Hepatocellular Carcinoma Receiving PD-1/PD-L1 Inhibitors.Journal of hepatocellular carcinoma · 2026Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 2 countries.
Funding
Abstract
Alkaline phosphatase (ALP) is an evolutionary conserved enzyme and widely used biomarker in clinical practice. Tissue-nonspecific alkaline phosphatase (TNALP) is one of four human isozymes that are expressed as distinct TNALP isoforms after posttranslational modifications, mainly in bone, liver, and kidney tissues. Beyond the well-known effects on bone mineralization, the bone ALP (BALP) isoforms (B/I, B1, B1x, and B2) are also involved in the pathogenesis of ectopic calcification. This narrative review summarizes the recent clinical investigations and mechanisms that link ALP and BALP to inflammation, metabolic syndrome, vascular calcification, endothelial dysfunction, fibrosis, cardiovascular disease, and mortality. The association between ALP, vitamin K, bone metabolism, and fracture risk in patients with chronic kidney disease (CKD) is also discussed. Recent advances in different pharmacological strategies are highlighted, with the potential to modulate the expression of ALP directly and indirectly in CKD-mineral and bone disorder (CKD-MBD), e.g., epigenetic modulation, phosphate binders, calcimimetics, vitamin D, and other anti-fracture treatments. We conclude that the significant evidence for ALP as a pathogenic factor and risk marker in CKD-MBD supports the inclusion of concrete treatment targets for ALP in clinical guidelines. While a target value below 120 U/L is associated with improved survival, further experimental and clinical research should explore interventional strategies with optimal risk-benefit profiles. The future holds great promise for novel drug therapies modulating ALP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.